CKD Bio Corp.

A063160

KR7063160006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 20/05/2024 am IST			5-day change	1st Jan Change
23,900 ^KRW	-0.42%		-2.05%	+0.21%

2023	CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	CKD Bio Corp.(KOSE:A063160) dropped from S&P Global BMI Index	CI

Korea Securities Finance Corporation acquired 4.11% stake in Ckd Bio Corporation.

January 09, 2015 at 09:30 am IST

Korea Securities Finance Corporation acquired 4.11% stake in Ckd Bio Corporation (KOSE:A063160) on January 9, 2015. Korea Securities Finance acquired 0.21 million shares of Ckd Bio Corporation.

Korea Securities Finance Corporation completed the acquisition of 4.11% stake in Ckd Bio Corporation (KOSE:A063160) on January 9, 2015.

Latest news about CKD Bio Corp.

CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
CKD Bio Corp.(KOSE:A063160) dropped from S&P Global BMI Index	18/23/18	CI
CKD Bio Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
CKD Bio Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
CKD Bio Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
CKD Bio Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	17/22/17	CI
CKD Bio Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/21/15	CI
Exclusive: South Korea's GL Rapha to ship out 10 million Sputnik Light COVID-19 shots this month	14/21/14	RE
Boryung Pharmaceutical : S.Korea's GL Rapha to ship out 10 mln Sputnik Light COVID-19 shots this month	14/21/14	RE
CKD Bio Corp.(KOSE:A063160) added to S&P Global BMI Index	21/20/21	CI
Chong Kun Dang Holdings Corp. completed the acquisition of additional 35.67% stake in Ckd Bio Corporation for KRW 61.6 billion.	12/16/12	CI
Chong Kun Dang Holdings Corp. made an offer to acquire an additional 35.67% stake in Ckd Bio Corporation for KRW 55.9 billion.	19/16/19	CI
Korea Securities Finance Corporation acquired 4.11% stake in Ckd Bio Corporation.	09/15/09	CI
Ckd Bio Corporation Announces Earnings Results for the Full Year Ended December 31, 2012	20/13/20	CI

Chart CKD Bio Corp.

Duration

Period

More charts

Company Profile

CKD Bio Corp. is a Korea-based company specialized in the manufacturing of pharmaceutical products. The Company mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. It also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The Company distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CKD BIO CORP.	+0.21%	9.64Cr
ELI LILLY AND COMPANY	+34.35%	71TCr
NOVO NORDISK A/S	+29.39%	58TCr
JOHNSON & JOHNSON	-3.49%	36TCr
MERCK & CO., INC.	+20.15%	33TCr
ABBVIE INC.	+6.19%	29TCr
ASTRAZENECA PLC	+14.11%	24TCr
ROCHE HOLDING AG	-3.03%	21TCr
NOVARTIS AG	+10.02%	21TCr
AMGEN INC.	+9.21%	17TCr

Other Pharmaceuticals

CKD Bio Corp.

Equities

A063160

KR7063160006

Pharmaceuticals

Korea Securities Finance Corporation acquired 4.11% stake in Ckd Bio Corporation.

Latest news about CKD Bio Corp.

Chart CKD Bio Corp.

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals